Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.24 and traded as low as $0.2345. Northwest Biotherapeutics shares last traded at $0.2633, with a volume of 6,559,719 shares trading hands.
Northwest Biotherapeutics Stock Down 0.8%
The stock’s 50-day moving average price is $0.21 and its 200 day moving average price is $0.24. The firm has a market cap of $416.47 million, a price-to-earnings ratio of -0.01 and a beta of -0.74.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
See Also
- Five stocks we like better than Northwest Biotherapeutics
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
